

Date Finalized: October 2025

1

# Inflammatory Bowel Disease Enhanced Recovery After Surgery Pathway Synopsis

# **Inflammatory Bowel Disease: Prior to Surgery Day Algorithm**

#### Inclusion criteria:

Any patient > 4 years old undergoing elective surgery for Crohn's disease or ulcerative colitis:

· Laparoscopic Ileocecetomy



QR code for mobile view

## Medication/Diet Instructions Received (at Surgery Clinic and PAT (if indicated):

- Medication:
  - Patient takes all normal daily medications night prior to surgery unless specifically instructed to stop
- Diet:
- · Standard NPO guidelines
- 2-3 hrs prior to surgery:
   Carbohydrate-rich drink: Gatorade,
   Powerade, or Pedialyte
- Arrival time/location

#### **ERAS Handouts**

- ERAS overview handout (English)
- ERAS overview handout (Spanish)

# Patient with inflammatory bowel disease scheduled for surgery Surgery Clinic Visit (and PAT visit if indicated) Introduction to ERAS principles, e.g., multimodal analgesia, encouraging PO intake, etc Pain management and regional anesthesia Bowel program regimen night before surgery Medication/Diet instructions Discuss anesthesia risks and plan (including mitigation of pre-op anxiety) Provide and review ERAS overview handouts

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.

Date Finalized: October 2025

2

# **Inflammatory Bowel Disease: Preoperative to Discharge Algorithm**

#### **Preoperative Care** Inclusion criteria: Any patient > 4 years old undergoing elective surgery for Crohn's disease **Preoperative Care** Carbohydrate-rich drink up to 2 hours before surgery or ulcerative colitis: Celecoxib PO 50 mg for patients 10 - 25 kg, 100 mg for pts ≥ 25 kg · Laparoscopic ileocecectomy Contraindicated for patients with chronic renal failure, NSAID allergy or sulfa QR code for mobile view **Celecoxib Options** Anxiolysis - midazolam (unless contraindicated) per anesthesia team · Open and mix with a small amount of clear liquid if patient is unable to swallow pills Intraoperative Intraoperative Medication Bundle Maintenance of Anesthesia Regional Anesthesia Volatile or TIVA maintenance at discretion of Antibiotics: \*Please involve an APS physician\* anesthesiologist Discuss at huddle · Discuss with surgeon at huddle TIVA preferred if history of PONV Administer before incision • Transverse Abdominal Plane (TAP) Blocks Normothermia: Ropivacaine 0.2% 0.5 ml/kg up to 20 ml per Antiemetics: Room temperature set to 70° F Amisulpride 5 mg for pts ≥ 50 kg at beginning side Utilize Bair Hugger · Be mindful of toxic local anesthetic dosages Goal for intraoperative temperature Dexamethasone 0.1 mg/kg (max 8 mg) when multiple blocks are performed 36° - 38° C Ondansetron 0.15 mg/kg (max 8 mg) Adjuncts: 1 mcg/kg clonidine to block solution • Euvolemia: unless contraindicated Goal is clinical euvolemia Multimodal analgesia: (zero fluid balance, no net weight gain on POD Methadone 0.1 mg/kg (max 10 mg) at Surgeon injects local if no regional anesthesia beginning of case Plasmalyte at 3 - 7 ml/kg/hr • IV acetaminophen 10 - 15 mg/kg at beginning (additional as clinically indicated) of case · Ketamine 0.5 mg/kg - 1 mg/kg bolus at beginning of case or consider infusion · Consider dexmedetomidine bolus at end of \* Ketorolac **SHOULD NOT** be given Transfer to PACU intra-operatively\* Limit IV opioids: Fentanyl prn Avoid long-acting opioids Postoperative -Inpatient to Discharge Goals of care prior to discharge PONV & Diet **Postoperative Pain Management** Ambulation **Bowel regimen** Daily bowel movement · Avoid use of NG tube (if possible) · Minimize long-acting opioids Encourage ambulation • Decrease IV fluids once patient is with prescribed regimen · Acetaminophen - scheduled 3x/day (if patient is (refer to orders) tolerating liquids and (10 mg/kg/dose q 4 hrs prn) allowed to ambulate discontinue thereafter · Ibuprofen - scheduled independently) · Start clear liquid diet -and-(10 mg/kg/dose given q 6 hrs prn) -oradvance as tolerated Oxycodone - transition to PO majority of day out of independent of bowel (0.1 mg/kg/dose given q 4 hrs prn) bed function once tolerating clears Consider P.T. consult Ondansetron 0.1 mg/kg Diazepam 0.05 - 0.1 mg/kg (max 5 mg) PRN q 6 hrs (max 8 mg) q 6 hrs prn for muscle spasms

Discharge home with post-operative follow up visit in 2 - 6 weeks

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.



Date Finalized: October 2025

3

# **Table of Contents**

Colorectal Inflammatory Bowel Disease: Prior to Surgery Day Algorithm	1
Colorectal Inflammatory Bowel Disease: Preoperative to Discharge Algorithm	2
Objective of ERAS Pathway	4
Background	
Target Users	4
Target Population	4
Core Principles of ERAS in Pediatric IBD (Perez & Raval, 2024; Rafeeqi & Pearson, 2021)	4
Additional Questions Posed by the ERAS Committee	4
Key Metrics To Be Monitored:	5
Value Implications	5
Organizational Barriers and Facilitators	5
Bias Awareness	5
Order Sets	5
ERAS Pathway Preparation	5
Inflammatory Bowel Disease ERAS Committee Members and Representation	5
ERAS Development Funding	6
Approval Process	6
Implementation & Follow-Up	6
Disclaimer	6
References	7

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.



Date Finalized: October 2025

1

# **Objective of ERAS Pathway**

The objectives of the Inflammatory Bowel Disease (IBD) ERAS pathway are to minimize the variation of care for the patient undergoing colorectal surgery, starting with the pre-admission testing visit and continuing through hospital discharge.

# **Background**

Inflammatory bowel diseases (IBD), including Crohn's disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU), are chronic gastrointestinal conditions, with up to 30% of cases presenting in childhood (Dipasquale et al., 2022). Within 10 years of diagnosis, 20-30% of pediatric patients require surgery to improve quality of life (Dipasquale et al., 2020, 2022, 2024; Turunen et al., 2009). Optimizing perioperative care is essential, as children with IBD often experience intense physical stress responses to conservative approaches, which typically involve prolonged fasting, bed rest, bowel prep, drainage tubes, catheters, and opioid-based pain management (Kain et al., 2006; Kehlet, 2008).

The Enhanced Recovery After Surgery (ERAS) program offers a patient-centered, evidence-based alternative, focusing on perioperative education, tailored anesthesia, minimally invasive techniques, early mobilization, reduced fasting, and selective drain use (Wilmore & Kehlet, 2001; Rafeeqi & Pearson, 2021). The implementation of ERAS for various surgical procedures in children continues to emerge. Studies have shown that there is a reduction in length of stay and accelerated rehabilitation after surgery when ERAS protocol is implemented (Rafeeqi et al., 2021; Su et al., 2023). The creation of the Inflammatory Bowel Disease Enhanced Recovery After Surgery (ERAS) pathway aims to standardize care, minimize opioid use, enhance infection prevention and wound healing, accelerate return of bowel function and oral intake, and shorten hospital stays.

# **Target Users**

- Physicians (Anesthesiologists, Fellows)
- Surgeons (Pediatric General Surgery)
- Advanced Practice HealthCare Professionals (APRNs, PA-C)
- Nurses

# **Target Population**

# Inclusion Criteria

- Any patient > 4 years old undergoing elective surgery for Crohn's disease or ulcerative colitis
  - Laparoscopic ileocecectomy

## Core Principles of ERAS in Pediatric IBD (Perez & Raval, 2024; Rafeeqi & Pearson, 2021)

- **Preoperative Counseling:** Educates patients and families on ERAS, pain management, and recovery expectations.
- Nutritional Support: Includes a nutritional assessment and personalized support before or after surgery.
- Modified Fasting: Clear liquids allowed until 2 hours before anesthesia; solids until 6 hours prior.
- **Minimally Invasive Surgery:** Uses less invasive techniques than traditional surgery to reduce recovery time.
- **Early Mobilization:** Patients begin moving the day after surgery to support healing.
- **Early Feeding:** Oral intake resumes the evening of surgery or the next day, often with immune-supportive formulas.

## **Additional Questions Posed by the ERAS Committee**

No clinical questions were posed for this review.

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.



Date Finalized: October 2025

5

# **Key Metrics To Be Monitored:**

Pre-Op	Intra-Op		Post-Op
Carb-rich drink	Dexamethasone/ Ondansetron	Acetaminophen	PONV PACU score
	Regional Anesthesia	Ketorolac	Opioids
	Euvolemia	Avoidance of Long-Acting Opioids	Time to diet
	Antibiotics administered prior to incision	Normothermia	Length of stay

# **Value Implications**

The following improvements may increase value by reducing healthcare costs and non-monetary costs (e.g., missed school/work, loss of wages, stress) for patients and their families, as well as reducing costs and resource utilization for healthcare facilities.

- Decreased inpatient length of stay
- Decreased unwarranted variation in care
- Improved communication between patients and care team throughout the perioperative period
- Improved post-operative pain control

# Organizational Barriers and Facilitators Potential Barriers

Variability of the acceptable level of risk among providers

## **Potential Facilitators**

- Collaborative engagement across care continuum settings during ERAS development
- High rate of use of the ERAS pathway

#### **Bias Awareness**

Bias awareness is our aim to recognize social determinants of health and minimize healthcare disparities, acknowledging that our unconscious biases can contribute to these inequities

## **Order Sets**

• There are no order sets associated with this ERAS pathway

# **Associated Policies**

There are no policies associated with this ERAS pathway

#### **Education Materials**

- ERAS overview handout
  - o Intended to be a general handout encompassing the key concepts and plan for an ERAS pathway
  - Found on the CM external website for each ERAS pathway
  - o Available in English and Spanish

# **ERAS Pathway Preparation**

This pathway was prepared by the EBP Department in collaboration with the Inflammatory Bowel Disease ERAS Pathway Committee, composed of content experts at Children's Mercy Kansas City. If a conflict of interest is identified, the conflict will be disclosed next to the committee member's name.

# **Inflammatory Bowel Disease ERAS Committee Members and Representation**

- Emily Weisberg, MD | Anesthesiology | Committee Chair
- Tolu Oyetunji, MD, MPH, MBA | Pediatric General Surgery | Committee Co-Chair

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.



Date Finalized: October 2025

6

- Shawn St. Peter, MD | Pediatric General Surgery | Committee Member
- Efua Bolouvi, MD | Pediatric General Surgery Fellow | Committee Member
- Nichole Doyle, MD, FASA, FAAP | Anesthesiology | Committee Member
- Christian Taylor, MD | Anesthesiology | Committee Member
- Gabriel Gallegos, MD | Anesthesiology | Committee Member
- Heather Sambol, RN, APRN | Anesthesiology | Committee Member

#### **EBP Committee Members**

- Todd Glenski, MD, MSHA, FASA | Anesthesiology, Evidence Based Practice
- Andrea Melanson, OTD, OTR/L | Evidence Based Practice

# **ERAS Development Funding**

The development of this ERAS pathway was underwritten by the following departments/divisions: Anesthesiology, General Pediatric Surgery, and Evidence Based Practice.

#### **Conflict of Interest**

The contributors to the Inflammatory Bowel Disease ERAS Pathway have no conflicts of interest to disclose related to the subject matter or materials discussed.

# **Approval Process**

This pathway was reviewed and approved by the EBP Department and the Inflammatory Bowel Disease ERAS
Committee, after the committee members garnered feedback from their respective divisions/departments.

#### **Review Requested**

Department/Unit	Date Obtained
Anesthesiology	October 2025
Pediatric General Surgery	October 2025
Evidence Based Practice	October 2025

# **Version History**

CISION INSCORP	
Date	Comments
October 2025	Version one – creation of algorithm, synopsis, and supportive educational materials

## **Date for Next Review:**

October 2028

# **Implementation & Follow-Up**

- Once approved, the ERAS pathway was presented to appropriate care teams and implemented.
- Key metrics will be assessed and shared with the appropriate care teams to determine if changes are needed.
- Pathways are reviewed every 3 years (or sooner) and updated as necessary within the EBP Department at CMKC. Pathway committees are involved with every review and update.

# **Disclaimer**

When evidence is lacking or inconclusive, options in care are provided in the supporting documents that accompany the ERAS pathway.

These ERAS pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment to determine what is in the best interests of the patient based on the circumstances existing at the time.

It is impossible to anticipate all possible situations that may exist and to prepare ERAS pathways for each. Accordingly, these ERAS pathways should guide care with the understanding that departures from them may be required at times.

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.



Date Finalized: October 2025

7

#### References

- Dipasquale, V., Catena, M. A., Paiano, L., Trimarchi, G., Romeo, C., Navarra, G., Mattioli, G., & Romano, C. (2024). Colectomy and health-related quality of life in children with ulcerative colitis. *Minerva pediatrics*, 76(1), 1–6. https://doi.org/10.23736/S2724-5276.20.05750-3
- Dipasquale, V., Laganà, F., Arrigo, S., Trimarchi, G., Romeo, C., Navarra, G., Mattioli, G., Gandullia, P., & Romano, C. (2022). Enhanced recovery care versus traditional care after surgery in pediatric patients with inflammatory bowel disease: A retrospective case-control study. *Biomedicines*, 10(9), 2209. https://doi.org/10.3390/biomedicines10092209
- Dipasquale, V., Antonelli, E., Cannavò, L., Cavatoi, G., Romeo, C., Trimarchi, G., Navarra, G., & Romano, C. (2020). Surgery-related quality of life of pediatric patients with Crohn's disease. *Frontiers in pediatrics*, *8*, 608370. https://doi.org/10.3389/fped.2020.608370
- Kain, Z. N., Mayes, L. C., Caldwell-Andrews, A. A., Karas, D. E., & McClain, B. C. (2006). Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. *Pediatrics*, *118*(2), 651–658. https://doi.org/10.1542/peds.2005-2920
- Kehlet, H. (2008). Fast-track colorectal surgery. The Lancet, 371(9615), 791-793.
- Perez, M.N. & Raval, M.V. (2024). Evolution of enhanced recovery for children undergoing elective intestinal surgery. Seminars in Pediatric Surgery, 33(2), 151400. doi.org/10.1016/j.sempedsurg.2024.151400
- Rafeeqi, T., & Pearson, E. G. (2021). Enhanced recovery after surgery in children. *Translational gastroenterology and hepatology*, 6, 46. https://doi.org/10.21037/tgh-20-188
- Su, Y., Xu, L., Hu, J., Musha, J., & Lin, S. (2023). Meta-Analysis of enhanced recovery after surgery protocols for the perioperative management of pediatric colorectal surgery. *Journal of Pediatric Surgery*, *58*(9), 1686–1693. https://doi.org/10.1016/j.jpedsurg.2022.11.017
- Turunen, P., Ashorn, M., Auvinen, A., Iltanen, S., Huhtala, H., & Kolho, K. L. (2009). Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study. *Inflammatory bowel diseases*, 15(1), 56-62.
- Wilmore, D. W., & Kehlet, H. (2001). Management of patients in fast track surgery. *BMJ (Clinical research ed.)*, 322(7284), 473–476. https://doi.org/10.1136/bmj.322.7284.473

<sup>\*</sup> These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.